Skip to main content

Table 2 Patient baseline clinical characteristics

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

  Placebo (N = 27) Namilumab
20 mg (N = 28) 80 mg (N = 25) 150 mg (N = 28)
Mean duration of RA at screening, years 10.04 ± 8.880 9.02 ± 7.476 8.62 ± 8.501 7.35 ± 4.976
Positive rheumatoid factor at baseline 16 (59.3) 16 (57.1) 12 (48.0) 18 (64.3)
Anti-citrullinated peptide antibodies at baseline 20 (74.1) 19 (67.9) 12 (48) 21 (75)
Mean MTX dose at baseline, mg/week 15.73 ± 4.04 16.54 ± 4.741 16.06 ± 4.370 15.96 ± 4.238
Type of failure of prior treatment
 MTX-IR 23 (85.2) 23 (82.1) 22 (88.0) 24 (85.7)
 TNF-IR 4 (14.8) 5 (17.9) 3 (12.0) 4 (14.3)
Corticosteroid use at baseline: yes 6 (22.2) 14 (50.0) 7 (28.0) 9 (32.1)
Mean DAS28-CRP score 5.71 ± 1.021 5.62 ± 0.931 5.63 ± 0.774 5.71 ± 1.122
 Mean DAS28-ESR score 7.19 ± 1.033 7.07 (0.876) 6.99 (0.741) 7.2 (1.023)
 Mean 66 swollen joint count 12.4 ± 8.78 12.8 (9.13) 15.8 (10.92) 13.6 (7.00)
 Mean 68 tender joint count 23.0 ± 13.12 24.1 (11.91) 25.4 (12.49) 24.2 (13.24)
Mean patient’s global assessment of disease activity 68.6 ± 17.6 68.8 ± 15.17 65.9 ± 15.69 66.8 ± 16.27
Mean patient assessment of pain (VAS), mm 77.3 ± 17.43 75.0 ± 17.73 72.6 ± 13.7 69.3 ± 19.69
Mean physician’s global assessment of disease activity (mm) 68.6 ± 17.22 68.8 ± 15.17 65.9 ± 15.69 66.8 ± 16.27
 Mean HAQ-DI 1.84 ± 0.67 1.61 ± 0.509 1.52 ± 0.516 1.49 ± 0.605
 Median CRP, mg/L 7.91 3.95 6.29 9.41
 Mean CRP, mg/L 17.12 ± 22.63 12.24 ± 15.4 8.92 ± 8.9 24.55 ± 60.5
 Mean MBDA score 48.15 ± 17.515 47.92 ± 20.17 41.91 ± 15.47 48.77 ± 17.75
 Mean C1M, ng/mL 35.45 ± 19.355 35.65 ± 24.99 35.36 ± 26.26 46.68 ± 45.56
SF-36 mental health 49.1± 17.92 50.4 ± 17.19 57.2 ± 18.08 50.6 ±18.24
SF-36 vitality 30.1 ± 17.51 31.5 ± 14.6 36.1 ± 14.35 31.7 ± 16.67
  1. Values are mean ± SD or n (%) unless otherwise indicated. CRP C-reactive protein, DAS28 Disease Activity Score 28, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire Disability Index, MBDA multibiomarker disease activity, MTX methotrexate therapy, MTX-IR inadequate response to methotrexate therapy, RA rheumatoid arthritis, TNF-IR inadequate response or intolerance to an anti-tumour necrosis factor biologic therapy, VAS visual analogue scale, SF-36 36-Item Short-Form Health Survey
\